The EPS beat is notable for a pre-revenue biotech, but the JANX008 discontinuation adds pipeline risk. Monitor upcoming JANX007 data in 1H 2027 and JANX011 update in 2H 2026. Cash runway supports operations into late 2027. The BMS partnership provides partial revenue visibility.
Price Chart
Executive Summary
Janux Therapeutics reported Q1 2026 EPS of -$0.39, a 22% beat vs consensus of -$0.50, driven by a $35M BMS milestone payment that generated $3.7M in collaboration revenue. The company discontinued JANX008 (EGFR-TRACTr) but initiated JANX014 and maintained strong cash position of $956M. The net loss slightly widened to $24.4M from $23.5M YoY.
Key Financial Metrics
Key Facts
- EPS of -$0.39 beat consensus -$0.50 by 22%
- Collaboration revenue $3.7M from BMS milestone, vs $0 in prior year
- Discontinued JANX008 (EGFR-TRACTr) after Phase 1a; pipeline focus on JANX007, JANX014, JANX011
- Cash, equivalents, and short-term investments $956M, down slightly from $967M at year-end
- Net loss $24.4M vs $23.5M in Q1 2025
- R&D spend $26.8M, up from $25.1M YoY
Financial Impact
Q1 operating loss $34.2M; cash burn remains manageable with $956M runway
Risk Factors
- Discontinuation of JANX008 may signal platform limitations or safety/efficacy issues
- No approved products; valuations hinge on clinical data readouts
- Cash burn rate increasing slightly; dilution risk if milestones delay
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-211964 |
| Document: janx-20260507.htm | 0001193125-26-211964 |
| Document: 0001193125-26-211964-index-headers.html | 0001193125-26-211964 |
| Document: 0001193125-26-211964-index.html | 0001193125-26-211964 |
| Document: 0001193125-26-211964.txt | 0001193125-26-211964 |
| 8-K Data (Synthetic) | 0001193125-26-211964 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 23, 2026 18w ago | 8-K | $14.64 $16.86 | ▲ +15.16% | ▲ +12.33% | $17.26 (+17.90%) |
Jun 11, 2026 19w ago | Institutional Cluster | $13.66 $20.24 | ▲ +48.17% | ▲ +43.77% | $17.26 (+26.35%) |
May 7, 2026 24w ago | 8-K | $14.18 $15.96 | ▲ +12.59% | ▲ +7.75% | $17.26 (+21.76%) |
Feb 28, 2026 34w ago | Institutional Cluster | $13.42 $14.40 | ▲ +7.30% | ▼ −2.02% | $17.26 (+28.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers